Beijing / Singapore:
China National Biotech Group (CNBG) said on Tuesday that its experimental coronavirus vaccine has triggered antibodies in clinical trials and that the company has planned for late human trials abroad.
No vaccines have been concretely proven to be able to effectively protect people from the virus that killed more than 400,000 people, while many candidates are in various stages of development globally.
The vaccine, developed by the Wuhan-based research institute affiliated with Sinofarm, the parent company of CNBG, found that high-level antibodies were induced in all people without serious adverse reactions, according to preliminary data from a clinical trial conducted in April 2010 . Healthy participants from 18 to 59 years of age.
CNBG said it is seeking opportunities for late stage and large-scale Phase 3 trials abroad.
“[We] Many countries have achieved cooperative intentions with companies and institutions, ”the company said in a statement.
State media reported that the vaccine candidate, with a different experimental shot developed by Sinopharm’s unit, has been introduced to government employees traveling abroad to Chinese employees, as developers seek more information about their efficacy.
China has five vaccine candidates for COVID-19 in human trials, the highest in any country.
China’s vaccine maker Synovac Biotech (Synovac) released the weekend’s positive preliminary clinical trial results for its potential vaccine candidate, which is expected to be tested in a Phase 3 trial in Brazil.